Toxicity of antilipidemic agents: Facts and fictions
- Cite this article as:
- Xydakis, A.M. & Jones, P.H. Curr Atheroscler Rep (2003) 5: 403. doi:10.1007/s11883-003-0012-3
- 40 Downloads
Dyslipidemias, particularly elevated low-density lipoprotein and low high-density lipoprotein cholesterol, are associated with increased cardiovascular morbidity and mortality and frequently require the use of lipid-lowering drugs to reduce risk. These drugs include statins, fibrates, niacin, and intestinal-acting drugs such as bile acid resins and ezetimibe, which can be used as monotherapy or in combination. Short- and long-term safety concerns often influence the selection of a lipid-altering medication. A balance of efficacy with a favorable safety and tolerability profile is necessary for optimal therapeutic benefits. Recent evidence suggests that there may be differences in the adverse event potential among the available lipid-altering drugs, even within the same class. Awareness of clinically relevant adverse events with monotherapy may assist in the safe selection of individualized lipid-lowering therapy regimens, as well as the potential for drug-drug interactions that may pose a unique challenge in selecting combination drug regimens.